Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Inhibition of the epidermal growth factor receptor (EGFR) is an established treatment that extends patient survival across a variety of tumor types. EGFR inhibitors fall into two main categories: anti-EGFR monoclonal antibodies, such as cetuximab and panitumumab, and first-generation tyrosine kinase inhibitors, such as afatinib, gefitinib, and erlotinib.
The recent retrospective series by Wahl et al1 reported the results of 224 patients with inoperable nonmetastatic hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) or stereotactic body radiotherapy (SBRT). The authors acknowledged the unbalanced populations and used an inverse probability of treatment weighting in the Kaplan-Meier method and Cox models to account for the treatment-related bias.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
